While more research and trials are needed before zuranolone can be widely available, these promising outcomes suggest a potential breakthrough in postpartum depression treatment. It is heartening to see pharmaceutical companies investing in developing new therapies that target specific mental health conditions. This ongoing commitment to improvement allows us to envision a day when effective treatments for postpartum depression become accessible to all mothers in need.
To learn more about this game-changing drug and the study’s findings, we encourage you to explore the underlying research!
Sage Therapeutics Inc and Biogen’s experimental drug to treat postpartum depression met the main goal of a late-stage study, the companies said on Wednesday. The drug, zuranolone, showed improvement in depressive symptoms among women with postpartum depression at day 15. It…